- Exchange: ISDX
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Specialty Pharmaceuticals
Snapshot for Vernalis PLC (VER)
| Open: | - | Day's Range: | - | Volume: | 0 |
|---|---|---|---|---|---|
| Previous Close: | 21.50 | 52wk Range: | 21.00 - 23.50 | 1-Yr Rtn: | - |
Key Statistics for VER
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. UKX | - |
| Earnings Per Share (GBP) (ttm) | - |
| Est. EPS (GBP) (12/2013) | -0.1450 |
| Est. PEG Ratio | - |
| Market Cap (M GBP) | 0.00 |
| Shares Outstanding (M) | 0.00 |
| 30 Day Average Volume | 7,305 |
| Price/Book (mrq) | - |
| Price/Sale (ttm) | - |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/01/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for VER
Company Profile & Key Executives for VER
Vernalis plc is a revenue generating development stage pharmaceutical company which has a broad pipeline of research and development programs. The Company is focused on developing products for the US prescription cough and cold market. The Company derives pipeline candidates both from collaborations with global pharmaceutical businesses and their own research activities.
| Ian GarlandChief Executive Officer | David MackneyChief Financial Officer |
| Kevin KissaneSecretary |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
VER News
-
Industry News
Advertisement
- 1
- 2
- 3
- 4
- 5
Advertisement
Sponsored Links
Advertisements
Rate this Page